Novartis AG (NVS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite the lack of discussion on strategic initiatives and operational updates, the financial performance is strong with a 7% revenue increase and a 20% EPS rise. Core operating income also grew by 15%. These robust financial metrics, coupled with increased R&D investment, suggest a positive outlook. The absence of concerning details in the Q&A section further supports a positive sentiment.
Key Financial Performance
Revenue $13.2 billion, a 7% increase year-over-year, driven by strong performance in key growth drivers such as Entresto, Kesimpta, and Pluvicto.
Core Operating Income $4.5 billion, a 15% increase year-over-year, reflecting higher sales and improved gross margin.
Free Cash Flow $3.8 billion, a 10% increase year-over-year, supported by higher operating income and favorable working capital movements.
Research and Development (R&D) Expenses $2.1 billion, a 5% increase year-over-year, attributed to increased investments in priority development programs.
Earnings Per Share (EPS) $1.50, a 20% increase year-over-year, driven by higher core operating income and share buybacks.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve risks, uncertainties, and other factors that could lead to materially different results than anticipated.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors Zachary
Baker Rothschild
Chouhan Intrinsic
Citigroup Inc
Co
Division EDT
Division Gordon
Division Graham
Division Leuchten
Division Naresh
Division Quigley
Division Sachin
Division Simon
Division Steve
Division Vosser
Division Weston
Dunn Guggenheim
EDT Kerry
Glyn Parry
Gordon Barclays
Graham Glyn
Health Advisors
Inc Research
Intrinsic Health
Jefferies LLC
Kerry Holford
LLC Research
Leuchten Jefferies
Mehta Chief
Ms Head
Mukul
Officer
Research Division
NVS Transcript
Novartis AG (NVS) Q1 2026 Earnings Call Transcript
Positive4-28
Despite the lack of discussion on strategic initiatives and operational updates, the financial performance is strong with a 7% revenue increase and a 20% EPS rise. Core operating income also grew by 15%. These robust financial metrics, coupled with increased R&D investment, suggest a positive outlook. The absence of concerning details in the Q&A section further supports a positive sentiment.
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Positive2-4
The earnings call summary and Q&A reveal strong financial performance, growth in key products, and strategic market expansion. Despite some uncertainties, management's optimistic guidance and robust pipeline, including new drug approvals and market opportunities, indicate positive sentiment. The announced growth in free cash flow and strategic focus on oncology and global launches further bolster confidence. Adjustments in the HORIZON trial timeline and management's evasive responses slightly temper the outlook, but overall, the sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call summary indicates a positive outlook with strong sales growth, strategic product expansions, and a significant share buyback program. Despite some margin pressure from generic competition, Novartis plans to offset it with productivity improvements. The Q&A reveals confidence in product launches and market strategies, with no major negative sentiments from analysts. The upgraded guidance and share buyback plan further support a positive sentiment, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
NVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
